COVID-19 Vaccine Now Available for Ages 5-11 at Cohen Children’s Medical Center

Children ages 5-11 and their parents are one step closer to ending the pandemic after Cohen Children’s Medical Center today began offering Pfizer-BioNTech’s kid-size coronavirus disease 2019 (COVID-19) vaccine. The Center for Disease Control and Prevention signed off on the latest age group to be vaccinated – representing 28 million Americans – and clearing the way for the families of seven youngsters to be the first at Northwell Health.

The patients and their parents, many of whom are physicians at the hospital, were greeted by Charles Schleien, MD, senior vice president and chair of pediatrics at Northwell Health and Cohen Children’s. Noting that this vaccination was a big step toward protecting those who are eligible, Dr. Schleien said, “In New York, six in 10 kids who are 12-and-over are already vaccinated. We need to get that number higher – and starting today, we need to chip away at vaccinating the newest group of eligible children. The vaccine is safe. It works – and it will be the way we successfully lower COVID stats across the region, nation and world.”

Sophia Jan, MD, chief of general pediatrics at Cohen Children’s, was on hand to vaccinate the youngsters and offer her support to their parents. “Being vaccinated will make it so much easier for our youngsters to get back to their normal lives,” said Dr. Jan. “Not only will they be able to get back to school and enjoy the holidays, but the important things – like hugging their parents and visiting their grandparents – we can start thinking about these things again.”

When interviewed as a group by a roomful of reporters, the newly vaccinated children all agreed that a moment of discomfort was well worth the relief of staying virus free. “Maybe one day we can go to school without masks,” they said.

In an effort to provide vaccinations to this newest eligible group, Northwell Health has established vaccination pods in Manhattan, Queens, Long Island and Westchester County. Locations and hours are:

  • Nassau County: (1 Marcus Ave, New Hyde Park, NY) Nov. 7 & 14, 9 a.m.-5 p.m.
  • Suffolk County: (5181 Sunrise Highway, Bohemia, NY) Nov. 6 & 13, 9 a.m.-5 p.m.
  • Suffolk County: (284 Pulaski Road, Greenlawn, NY) Nov. 11, 8 a.m.-8 p.m.; Nov. 18, Noon-8 p.m.
  • Suffolk County: (4 West 2nd Street, Riverhead, NY) Nov. 7 & 14, 9 a.m.-5 p.m.
  • Manhattan: (200 West 13th Street, New York, NY) Nov. 10, 3-7 p.m.; Nov. 13, 10 a.m.-3 p.m.
  • Queens: (95-25 Queens Blvd., Rego Park, NY) Nov. 6 & 13, 9 a.m.-9 p.m.
  • Westchester County: (480 North Bedford Road, Chappaqua, NY) Nov. 7 & 14, 9 a.m.-5 p.m.

To schedule a vaccine appointment, call (844) 919-VACC for the most up-to-date availability or go to: https://www.northwell.edu/coronavirus-covid-19/vaccine/locations.

 

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”